Shots:

• The spin-off of the Diabetes Care business will allow the BD to strengthen its growth profile- enables it to focus on its other core businesses. The transaction is expected to be completed in H1’22
• Standalone Diabetes Care business is expected to leverage its position as a global leader in insulin delivery and expand its presence in the large and high-growth diabetes market. The spinoff allows both BD and NewCo to enhance each company's focus on meeting the needs of their respective patients- customers- and stakeholders
• The BD’s diabetes care includes syringes- pen needles- and products for injecting insulin and other drugs

  Ref: BD | Image: BD